Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

<i>C</i>. <i>sinensis</i> induced prominently expressed TLR2 in mouse BECs. by Yuru Wang (846969)

Subjects:

Data from: Mistletoe host diversity decreases with elevation in a temperate rainforest of southern Chile: implications for frugivory by Victoria P. Fernández (11989404)

“…., J.I. Orellana, Fernández, V.P., G.C. Amico & R.F. Nespolo. 2025. Mistletoe host diversity decreases with elevation in a temperate rainforest of southern Chile: implications for frugivory. …”

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Data_Sheet_2_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.CSV by Brian E. Sedio (10875330)

“…To test this prediction, we compared patterns of chemical and morphological trait diversity of 140 woody plant species among seven temperate forests in North America representing 16.2°C variation in mean annual temperature (MAT), 2,115 mm variation in mean annual precipitation (MAP), and from 10 to 68 co-occurring species. …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Decrease of IL-6 and increase of IL-10 secretion in HESN derived-neutrophils after TLR4 stimulation. by Juan C. Hernandez (704571)

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

“…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…”

Data_Sheet_1_Pulmonary inflammation decreases with ultra-protective ventilation in experimental ARDS under VV-ECMO: a positron emission tomography study.docx by Guillaume Deniel (17990323)

“…</p>Results<p>Five pigs were randomized to each study group. Arterial O₂ partial pressure to inspired O₂ fraction were not significantly different between study groups after experimental ARDS induction (75 [68–80] mmHg in a PV group vs. 87 [69–133] mmHg in a UPV group, p = 0.20). …”